Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Initial Report from Shiraz Surgical Oncology Group

Hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used to treat peritoneal carcinomatosis (PC). The objective was to evaluate the outcomes of cytoreductive surgery (CRS) and HIPEC in our center.

In this retrospective study, data were collected from 43 patients with PC who underwent CRS-HIPEC in 2016 at Faghihi Hospital of Shiraz University of Medical Sciences. Outcomes were collected and analyzed. Analyses were conducted through SPSS 23. P-value < 0.05 was considered to be statistically significant.

The mean age of the patients was 52.23 ± 11.82 years. The participants in the study analysis consisted of 36 female (83.7%) and seven male patients (16.3%). The most common primary tumor was ovarian cancer (62.8%). Completeness of the cytoreduction score of CC0/CC1 was obtained in 87.7% of the patients. The 1- and 3- year overall survivals were 88% and 60%, respectively.

Our study supports that employing CRS and HIPEC for PC is feasible with acceptable morbidity in our center.